WO2013186570A1 - Nutritional product - Google Patents
Nutritional product Download PDFInfo
- Publication number
- WO2013186570A1 WO2013186570A1 PCT/GB2013/051561 GB2013051561W WO2013186570A1 WO 2013186570 A1 WO2013186570 A1 WO 2013186570A1 GB 2013051561 W GB2013051561 W GB 2013051561W WO 2013186570 A1 WO2013186570 A1 WO 2013186570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- decanoic acid
- acid
- composition
- decanoic
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims description 13
- 206010015037 epilepsy Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 89
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 87
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 82
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 38
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 28
- 235000019197 fats Nutrition 0.000 claims description 28
- 229930195729 fatty acid Natural products 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 28
- 150000004665 fatty acids Chemical class 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 235000014633 carbohydrates Nutrition 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 20
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 210000003470 mitochondria Anatomy 0.000 claims description 19
- 206010010904 Convulsion Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 230000004898 mitochondrial function Effects 0.000 claims description 13
- 230000001413 cellular effect Effects 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 230000002361 ketogenic effect Effects 0.000 claims description 10
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 6
- 235000011962 puddings Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 235000013351 cheese Nutrition 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000020186 condensed milk Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000014048 cultured milk product Nutrition 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 235000019541 flavored milk drink Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 235000004213 low-fat Nutrition 0.000 claims description 2
- 235000013310 margarine Nutrition 0.000 claims description 2
- 239000003264 margarine Substances 0.000 claims description 2
- 239000008268 mayonnaise Substances 0.000 claims description 2
- 235000010746 mayonnaise Nutrition 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000014059 processed cheese Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 17
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000000378 dietary effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 30
- 235000020887 ketogenic diet Nutrition 0.000 description 26
- 239000003925 fat Substances 0.000 description 22
- 230000037213 diet Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 9
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 9
- 102000006732 Citrate synthase Human genes 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 6
- 235000003441 saturated fatty acids Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000003240 coconut oil Substances 0.000 description 5
- 235000019864 coconut oil Nutrition 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 235000021241 α-lactalbumin Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000027721 electron transport chain Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004140 ketosis Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000008463 key metabolic pathway Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 235000021079 modified Atkins diet Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.
- Epilepsy covers a broad range of neurological disorders that are characterised by seizures. Seizures result from abnormal neuronal activity and manifest in a number of ways, including convulsions and loss of awareness. In many cases epilepsy can be managed by the use of anti-convulsive medication. However for a proportion of patients with epilepsy, treatment with conventional drugs can have minimal effect upon seizure activity. Although surgery is an option for treating patients suffering from certain seizures, for many individuals successful management can be achieved less invasively with the ketogenic diet.
- Ketogenic diets have a high fat and low carbohydrate content with sufficient protein for growth and repair; vitamin and mineral levels are typically inadequate and may be required to be provided as supplements. Ketogenic diets function by forcing the body to metabolise fat instead of carbohydrate as its energy source. Under low dietary carbohydrate conditions, fats are broken down into fatty acids and ketone bodies in the liver, and these compounds are utilised in further metabolic pathways for generating adenosine triphosphate (ATP) as a chemical energy source.
- ATP adenosine triphosphate
- Studies have shown a clear benefit of the ketogenic diet in treating intractable epilepsy in children and adults. Short-term trials have demonstrated that approximately half of those studied had at least a 50% reduction in seizures after 6 months, and approximately one third reached at least a 90% reduction. In certain cases, the ketogenic diet is sufficiently effective to enable a reduction in the levels of prescribed anti-epileptic medication and also to improve quality of life.
- Ketogenic diets must be strictly controlled to ensure effective seizure prevention whilst maintaining adequate nutritional value.
- the diets are developed and optimised on a case-by- case basis under medical supervision, and all food must be carefully measured and prepared. Deviation from the diet may result in the patient experiencing renewed seizures within a short period of time.
- ketogenic diets are difficult to manage in both children and adults. Current approaches to the ketogenic diet can be very restrictive and this can lead to poor compliance, particularly in adults.
- such diets can result in a number of side- effects (including problems of the digestive system, increased serum lipid levels, drowsiness, poor growth and increased risk of fractures), and are entirely unsuitable for certain patients. Identification of the active component(s) of the ketogenic diet responsible for supressing seizure activity therefore has the capability to dramatically simplify treatment and improve the quality of life for a significant number of patients with epilepsy.
- Ketones are the products of fat breakdown.
- the body normally burns glucose for energy.
- the body can use these ketones as a source of energy instead of glucose.
- Mitochondria are organelles present in almost every cell in the body. They play pivotal roles in a number of cellular processes, most prominently in energy metabolism. Provision of energy is achieved by the integrated function of the electron transport chain (ETC), which receives reducing equivalents from key metabolic pathways such as the tricarboxylic acid (TCA) cycle and fatty acid ⁇ -oxidation.
- ETC electron transport chain
- Compromised mitochondrial function may arise through inherited or acquired mutations in both nuclear and mitochondrial DNA, and may also be acquired as a result of exposure to environmental factors. Mitochondrial dysfunction is associated with a wide range of clinical conditions, which generally affect organs with high energy requirements such as muscle, liver, kidney and brain. A paucity of energy in the brain, in the form of ATP, leads to neurological impairment that can include seizures. Indeed, mitochondrial dysfunction has been linked to certain inherited and acquired epilepsies, although it is also associated with a number of other disease states, including diabetes, dementias including Alzheimer's disease, and Parkinson's disease.
- ketogenic diet increases mitochondrial function and biogenesis, and alleviation of epileptic seizures.
- ketogenic diet presents a number of challenges, products which target the same biological mechanisms are clearly highly desirable.
- the ketogenic diet has a number of characteristic metabolic effects including increased ketone body formation and elevated plasma levels of medium chain fatty acids. There is no known correlation between ketone body levels and seizure control, and relatively little research has been carried out on the effects of the increased fatty acid concentrations.
- decanoic acid a medium chain fatty acid that increases in plasma concentration as a result of a ketogenic diet in which MCT forms a part, has a direct effect on mitochondrial function and availability in cells in vitro.
- decanoic acid may be beneficial for the treatment of epilepsy, particularly in patients who currently require a ketogenic diet; diseases associated with inherited mitochondrial dysfunction; and patients with acquired mitochondrial disorders, including those with diabetes, Parkinson's disease and dementias including Alzheimer's disease.
- composition suitable for human consumption comprising a decanoic acid to octanoic acid ratio of 2:1 wt/wt or is substantially free from octanoic acid and optionally is substantially free from any other saturated fatty acid.
- the decanoic acid to octanoic acid ratio is at least 2: 1 wt/wt, at least 3:1 wt/wt, at least 4:1 wt/wt, at least 5:1 wt/wt, at least 6:1 wt/wt, at least 9:1 wt/wt, at least 10: 1 wt/wt, at least 15:1 wt/wt, at least 20:1 wt/wt, at least 30:1 wt/wt, at least 40: 1 wt/wt, at least 50:1 wt/wt, at least 60:1 wt/wt, at least 70:1 wt/wt, at least 80:1 wt/wt, at least 85:1 wt/wt, at least 90: 1 wt/wt, at least 95: 1 wt/wt, at least 98:1 wt/wt or at least 99:1 wt/
- the decanoic acid is greater than 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58% or 59% of the total weight of fatty acid content, at least 60% of the total weight of fatty acid content, at least 65% of the total fatty acid content, at least 70% of the total weight of fatty acid content, at least 80% of the total weight of fatty acid content, at least 90% of the total weight of fatty acid content, or is at least 99%, or 100% of the total weight of fatty acid content.
- the present invention may make use of a product which comprises pure or substantially pure decanoic acid.
- the present invention also envisages a composition which is free from or substantially free from mono- or poly-unsaturated fatty acids.
- a composition suitable for human consumption which has a ketogenic ratio of from 0.2 to 0.3:1.
- Other embodiments include, but are not limited to, ratios of 0.5: 1 , 1 :1 to 5: 1 , preferably up to 4: 1 , and wherein the majority of fat is decanoic acid.
- this composition has a ketogenic ratio of 2:1 to 4: 1.
- ketoogenic ratio we refer to the ratio of the weight of lipid to the sum of the weights of carbohydrate and protein.
- composition suitable for human consumption comprising proteins, fat and carbohydrates, which provides 2500 to 3100 kJ per 100 g dry mass, and wherein at least 50% of the fat is decanoic acid.
- composition of the third aspect of the present invention at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% 95%, 98%, 99% or 100% of the fat is decanoic acid.
- composition of the third aspect of the present invention does not include any mono- and/or polyunsaturated fatty acid.
- composition of the invention provides 2520 to 3780 kJ per 100 g dry mass. In another embodiment of the composition of the invention provides 2520 to 3180 kJ per 100 g dry mass.
- the weight amounts of lipid to the sum of proteins and carbohydrates is 1.0 to 1 , 2.0 to 1 , 5.0 to 1 , or say 2.0-5.0 to 1 , or 2.4- 4.0 to 1 , or 2.6-3.8 to 1.
- the composition is in the form of a human food stuff.
- the composition is in a form for delivering a dosage of at least about 5 g/l to 150 g/l decanoic acid per day.
- the dosage is about 5 g/l, 10 g/l, 15 g/l, 20 g/l, 30 g/l, 40 g/l, 50 g/l, 60 g/l, 70 g/l, 80 g/l, 90 g/l, 100 g/l, 1 10 g/l, 120 g/l, 130 g/l, 140 g/l, 150 g/l, 175 g/l, 200 g/l, 225 g/l, 250 g/l or 500 g/l decanoic acid per day.
- the composition is in the form of a complete nutritional product. In one embodiment of the compositions of the invention, the composition is in powdered form.
- the composition is in a spray dried form.
- the composition is in a form suitable for fortifying food or drink.
- the composition is in the form of a food stuff.
- the composition is in the form of an oil-in-water emulsion.
- the compositions according the present invention may be in the form of an oil, mayonnaise, margarine, low fat spread, a dairy product including yoghurts, a cheese spread, processed cheese, a dairy dessert, a flavoured milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soya product, pasteurised liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, liquid emulsion, spray dried powder, freeze dried powder, UHT pudding, Pasteurised pudding, gel, jelly, yoghurt or a food with a fat-based or water-containing filling.
- a fourth aspect of the present invention there is provided use of decanoic acid for the preparation of a medicament for the treatment of a disease associated with mitochondria dysfunction.
- medicament for the treatment of a disease associated with mitochondria dysfunction.
- immediatecament we include any of the compositions of the present invention, including a nutritional supplement or complete nutritional product.
- decanoic acid for the treatment of a disease associated with mitochondria dysfunction.
- the disease is epilepsy, diabetes, Parkinson's disease, dementias including Alzheimer's disease, or an inborn error of mitochondrial function.
- a method for the treatment or prevention of a disease associated with mitochondria dysfunction comprising administering an effective amount of decanoic acid to a patient in need of the same.
- a seventh aspect of the present invention there is provided a method of affecting the cellular content of mitochondria comprising administering decanoic acid to the cell.
- an eighth aspect of the present invention there is provided a method of affecting the cellular function of mitochondria comprising administering decanoic acid to the cell.
- a method of affecting the cellular availability of mitochondria comprising administering decanoic acid to the cell.
- a method of modulating the cellular energy supply comprising administering decanoic acid to the cell.
- the treatment of epilepsy includes the control of seizures.
- decanoic acid a method or use according to any one of the fourth to tenth aspects of the invention wherein the decanoic acid is administered in the form of a composition according to any one of the first to third aspects of the invention.
- decanoic acid the method or use according to any one of the fourth to tenth aspects of the invention in which a dosage of at least about 5 g/l to 250 g/l or at least about 5 g/l to 500 g/l decanoic acid is administered per day.
- the present invention can be summarised as relating to decanoic acid for use in the treatment of a disease associated with mitochondria dysfunction.
- Decanoic acid is also known as capric acid and is a saturated fatty acid of formula
- ketogenic diets By elucidating the mechanism associated with the benefits of ketogenic diets we overcome some of the problems associated with prior compositions by providing a highly effective product which can be formulated to increase its palatability and deliver a specific level of C10. Moreover it allows diseases to be treated by the use of C10 outside of the strict confines of the classic ketogenic diet.
- the classical version of the ketogenic diet uses ratios to determine and describe fat content.
- the ketogenic ratio represents the relationship between the grams of fat and the combined grams of protein and carbohydrate. In a 4:1 ratio there are four times as many grams of fat for every 1 g of protein and carbohydrate combined. The ratio is traditionally intended to regulate the degree of ketosis, with higher ratios theoretically stimulating greater ketosis.
- the MCT version of the ketogenic diet uses percentage energy from fat to determine and describe fat content.
- the other two versions of the ketogenic diet are the so- called modified Atkins diet and the low glycaemic (Gl) index diet, which encourage people to ingest a lot of fat.
- the ratio or total fat content can be altered during therapy to achieve nutritional goals and to optimize clinical benefit.
- the ratio can be in the range of 1.0:1 , 1.5:1 , 2.0:1 , 2.5:1 , 3.0:1 , 3.5:1 , 4.0:1 , 4.5:1 or 5.0:1.
- the ratio is 2.25:1 to 3.9:1.
- the ratio is 2.26 to 3.8:1 or 2.7-3.4:1.
- the ratio is 3.21 :1 , 3.23:1 , 3.24:1 , 3.25:1 , 3.26:1 , 3.27:1 , 3.28:1 or 3.29:1.
- Decanoic acid occurs naturally in e.g. coconut oil and palm kernel oil and it can be envisaged that these products could form the key basis of the diet.
- decanoic acid forms around 5 to 8% of the fatty acid composition of coconut oil.
- the fatty acid composition comprises from about 5 to 8 % of decanoic acid.
- octanoic acid comprises around 4.6 to 10% of the fatty acid composition of coconut oil. Since the present invention has identified that C8 is less beneficial than C10, one can envisage a food composition which the fatty acid composition comprises less than 10%, ideally less than 4.6% of octanoic acid.
- the lipid fraction useful in the present invention can be in the form of triglycerides, diacyl-glycerides, monoacyl-glycerides, phospholipids, lyso-phospholipids, cholesterol and glycolipids, with triglycerides being generally preferred.
- the amount of saturated fatty acids utilised is relatively high. In particular it is preferably between 23 and 50, more preferably 25-45, and even more preferably 33-44 g per 100 g lipids, on fatty acid basis.
- the saturated fatty acids have 8 to 24 carbon atoms.
- decanoic acid C10:0
- Decanoic acid thus provides e.g. 15-50, preferably 18-45, more preferably 23-44 g per 100 g lipids.
- a particular embodiment comprises 30-37 g decanoic acid per 100 g lipids.
- coconut oil or palm oil is a preferred source for at least 50%, preferably between 70 and 90 of the lipid fraction. The remainder of the lipid fraction can be selected from e.g.
- medium-chain triglyceride sources such as fractionated coconut oil, macadamia oil, palm oil or palm kernel oil, or long-chain triglyceride sources such as safflower oil, sesame seed oil, soy oil (which may be obtained from soybean), sunflower oil, high oleic sunflower oil, corn oil, canola oil, walnut oil, evening primrose oil, peanut oil, cottonseed oil, rapeseed oil, olive oil, fish oil, palm olein or algal oil, or mixtures thereof, preferably soybean oil (preferably between 2 and 30), medium-chain triglycerides (with fatty acids having 8-12 carbon atoms; between 0 and 14), marine oils (preferably between 0 and 14 wt.
- medium-chain triglycerides with fatty acids having 8-12 carbon atoms; between 0 and 14
- marine oils preferably between 0 and 14 wt.
- the present invention preferably does not include mono-unsaturated and/or polyunsaturated fatty acids. However, if present the amount of mono-unsaturated fatty acids is suitably between 25 and 48, preferably 28-43, more preferably 30-40 g per 100 g lipids (fatty acid basis). If present, the amount of polyunsaturated fatty acids (i.e. having two or more unsaturated bonds), to which the trans fatty acids have been excluded, is 16-40, preferably 20-30 g per 100 g lipids. It is preferred that the lipid fraction also comprises omega.-3 polyunsaturated fatty. In particular, the polyunsaturated fatty acids comprise more than 0.5, preferably 1.0-10 wt. %. The amount of trans fatty acids is below 20, preferably 0-10, more preferably 0.2-4 g per 100 g lipids.
- MCT oil is a food grade oil generally comprising more than 90 wt% fatty acids. Traditionally these fatty acids have been made up of saturated fatty acids having 8, 10 or 12 carbon atoms. Whilst MCT oil may have application in the present invention, preferred is the use of MCT based oil in which the majority of the saturated fatty acids are decanoic acid.
- decanoic acid represents at least 51 %, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 wt% of the fatty acid content of the composition useful in the present invention.
- the ratio of the saturated fatty acids of C10 to C8 is 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, 95:5 or 100:0.
- LCT oil is defined as a food grade oil that comprises 15% of fatty acids having 20 or more carbon atoms.
- the present invention may utilise an LCT oil, but preferably at a level of 1%, 0.5% or 0.1% or less per l 00 g.
- administration of the composition of C10 of the present invention may be by an oral route or another route into the gastro-intestinal tract or by parenteral routes.
- the forms for these modes of administration may include conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- the composition of C10 of the present invention can be formulated in a suitable form, which may be a dosage form.
- the form is generally suitable for oral administration, but the invention is also applicable to gastric tube feeding.
- Suitable forms may include tablets, dragees, capsules, gel caps, powders, granules, solutions, emulsion, suspension, coated particles, spray-dried particles and pills, which contain the composition of C10 of the present invention, and optionally one or more suitable pharmaceutically acceptable carriers.
- the composition of C10 can be inserted or mixed into a food substance.
- the composition of C10 of the present invention is in the form of a nutritional product.
- nutritional product we generally refer to the situation where the substance intended to supplement a diet; although in the present situation the composition may be in a form such that it is intended to be the sole item or a meal or diet, i.e. a so-called "complete" nutritional product.
- the present invention may be administered to subjects in the form of nutritional supplements, foods, beverages.
- a preferred type of food is a medical food, e.g. a food which is in a formulation to be consumed under medical supervision and which is intended for the specific dietary management of a disease or condition, such as in the ketogenic diet referred to above.
- the present invention may be realised in the form of a product which is suitable for complete nourishment of human beings, or as an oil emulsion or supplement or any other convenient product form.
- the product may be suitable for infants, children and adults.
- the product as well as comprising a lipid fraction in accordance with the teachings of the present invention may optionally comprise a protein fraction, a fraction of digestible carbohydrates, available and/or nonavailable carbohydrates, a nitrogen fraction and optionally, a vitamin fraction, a mineral/trace element fraction or other components as may be appropriate to provide a nutritional supplement or complete nutritional product.
- the protein fraction comprises preferably peptides larger than 8 amino acids, which can make the product unsuitable for parenteral administration, due to potential allergic reactions.
- proteins which have strong emulgating properties, such as certain caseins.
- products usable for reconstitution in water or liquid formula should preferably contain lysolecithin, tartaric esters or combinations thereof as stabilization system in order to obtain a product that is suitable for drinking.
- the product may preferably be solid or semi-solid, such as a powder, bar, pudding, etcetera.
- a semi-solid product is understood to be a product having a solid content of more than 40 g per 100 g ready to use product. More preferably the semi-solids are supplied as powder, which can be reconstituted in water to be used as a single, complete food.
- the powder may comprise of primary particles, agglomerated primary particles or mixtures of particles of various size. Such powders can be manufactured using methods known in the art, such as spray drying. Spray drying is preferred when aids are used to improve flowing characteristics.
- the product may also be in the form of an oil which could be used for frying etc.
- the dry product may be at least partly soluble in water, so as to allow ready make-up of a liquid food, if desired.
- the amount of digestible carbohydrates is 0-9, preferably 3.2-9, more preferably 4-8.6, even more preferably 5-8.2 g per 100 g dry mass.
- the amount of protein is 5-20, preferably 13-20, more preferably 13-18, more preferably 13.8-17, even more preferably 14.2-16.2 g per 100 g dry mass.
- the amount of lipids is 0, 0.1-100 g per 100 g dry mass, but may be 60-80, 63-75, or 65-72 g per 100 g dry mass.
- alpha-lactalbumin or ingredients which comprise high amounts of protein are particularly suitable.
- the presence of more than 20 wt % alpha-lactalbumin in the protein fraction of the product results in easy compliance with the requirements for leucine, lysine, methionine and cysteine, excellent palatability and digestion properties.
- Preferably more than 20%, more preferably 40-80 wt % of the protein fraction consists of alpha-lactalbumin.
- the digestible carbohydrate fraction can comprise food grade ingredients such as glucose syrup, maltodextrins, lactose, sucrose, galactose, ribose, etc. Though excellent products can be obtained in terms of efficacy when several of the other technical features as disclosed in this description are applied, best results in terms of avoidance of side effects and efficacy are obtained if the digestible carbohydrate fraction takes a specific form. It appears beneficial if at least 20%, preferably 30-90% of the digestible carbohydrate fraction is formed by a source of galactose or ribose. Lactose is considered as suitable ingredient for this purpose. In particular oxidative stress will decrease, when such ketogenic formula is consumed, which comprises such non-glucose digestible carbohydrates. Digestibility is determined by applying the Englyst 1999 method.
- the proteins, lipids, and carbohydrates preferably originate from at least two different sources, for example, the proteins at least partly from animal, especially milk, source, but optionally also partly from plant source, the lipids at least partly from vegetal source, and the carbohydrates at least partly from milk source, or from a combination of milk (lactose) and plant (glucose, maltodextrins etc.).
- the energy requirement may be calculated according to an individual's energy requirements.
- Useful products for feeding patients particularly paediatric epileptic patients, have an energy density of 3.8-12.6 kJ/ml preferably 4.6-8.4 kJ/ml and more preferably 5.0-7.2 kJ/ml.
- An energy density of 5.4-6.7 kJ/ml appears particularly useful when nourishing completely with the product.
- the energy density of the liquid formula is 8.4-12.6 kJ/ml
- the product may also be useful for intermediate fortification of the patient.
- the product usefully is relatively energy dense. In some embodiments, it provides 2520- 3780, or say 2520-3080, and preferably 2800-3040 kJ per 100 grams dry matter.
- the diet may provide 2500-3100 kJ per 100 grams dry matter, such as 2505, 2510, 2515, 2520, 2525, 2530, 2535 or 2540 to 3100, 3095, 3090, 3085 or 3080 kJ per 100 g.
- the diet comprises 2984, 2985, 2986, 2987, 2988, 2989 or 2990 kJ per 100 g.
- the product suitably after reconstitution to a liquid product, can be administered in an amount of between 50 and 200, preferably between 75 and 150 g per day, calculated as dry mass, for infants younger than 12 months, following general energy consumption recommendations, like has been described in the guidelines of the health authorities.
- the preferred daily amount calculated on dry mass is between 100 and 360, especially between 150 and 300 g.
- these amounts are 100-500, most preferably 150-340 g for providing most ketogenic potential, and at the same time a sufficient amount of essential amino acids, carbohydrate skeletons, and other nutrients and being well tolerated and safe.
- suitable products for use in the present invention are given below: Spray Dried Powder Formulation
- Vitamin A Mg ⁇ 21 ⁇ 53
- Mitochondrial enrichment was estimated by evaluation of citrate synthase activity (corrected for total cellular protein content). This enzyme is localised at the mitochondria, comprises part of the TCA cycle and is commonly used as a marker of mitochondrial enrichment. In order to gain further independent insight into mitochondrial function, the activity of the respiratory chain enzyme, Complex I, was also evaluated.
- a human neuroblastoma cell line (SH-SY5Y) was utilised throughout this study, except where stated. In brief, cells were exposed to a range (50 - 300 ⁇ , dissolved in 0.5% DMSO) of either octanoic or decanoic acid concentrations. After 6 days, the cells were harvested and citrate synthase activity was determined. Activity was expressed as nmol/min/mg of cellular protein.
- SH-SY5Y cells were prepared for electron microscopy (EM) analysis to assess mitochondrial density and morphology following treatment with decanoic acid.
- EM electron microscopy
- decanoic acid was validated in an independent cell line. Primary cultures of human fibroblasts were exposed to decanoic acid at a concentration of 250 ⁇ for 6 days. Following the incubation, citrate synthase activity was again assessed.
- Octanoic acid had no effect on the parameters studied. However, exposure of the SH-SY5Y cells to decanoic but not octanoic acid resulted in an increase in citrate synthase activity when compared to control cells (incubated with vehicle only). This effect was dose dependent (Fig 1), with a maximum, highly significant (p ⁇ 0.001), 30% increase occurring at a concentration of 250 ⁇ (expressed as nmol/min/mg cell protein):
- decanoic acid may also be beneficial. With regards to acquired disorders, this could include diabetes and neurodegenerative conditions such as Parkinson's disease and dementias including Alzheimer's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014031302A BR112014031302A2 (en) | 2012-06-15 | 2013-06-14 | nutritional product |
JP2015516688A JP2015522256A (en) | 2012-06-15 | 2013-06-14 | Nutritional products |
EP22202824.3A EP4162934A1 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
DK13730925.8T DK2861226T3 (en) | 2012-06-15 | 2013-06-14 | NUTRITIONAL PRODUCT INCLUDING DECANOIC ACID AND OCTANOIC ACID |
AU2013276254A AU2013276254A1 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
CA2876286A CA2876286C (en) | 2012-06-15 | 2013-06-14 | Nutritional products for treatment of disorders associated with mitochondrial dysfunction |
EP24165887.1A EP4371612A3 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
ES13730925T ES2933408T3 (en) | 2012-06-15 | 2013-06-14 | Nutritional product comprising decanoic acid and octanoic acid |
FIEP13730925.8T FI2861226T3 (en) | 2012-06-15 | 2013-06-14 | Nutritional product comprising decanoic acid and octanoic acid |
US14/406,957 US11344522B2 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
CN201380031426.7A CN104519880A (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
EP13730925.8A EP2861226B1 (en) | 2012-06-15 | 2013-06-14 | Nutritional product comprising decanoic acid and octanoic acid |
HK15109109.2A HK1208367A1 (en) | 2012-06-15 | 2015-09-17 | Nutritional product |
AU2018200433A AU2018200433A1 (en) | 2012-06-15 | 2018-01-18 | Nutritional product |
AU2019226282A AU2019226282A1 (en) | 2012-06-15 | 2019-09-09 | Nutritional product |
AU2021202459A AU2021202459B2 (en) | 2012-06-15 | 2021-04-22 | Nutritional product |
US17/746,250 US20220273602A1 (en) | 2012-06-15 | 2022-05-17 | Nutritional product |
AU2022253500A AU2022253500B2 (en) | 2012-06-15 | 2022-10-17 | Nutritional product |
AU2024205213A AU2024205213A1 (en) | 2012-06-15 | 2024-07-30 | Nutritional product |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1210699.3A GB201210699D0 (en) | 2012-06-15 | 2012-06-15 | Nutritional food |
GB1210699.3 | 2012-06-15 | ||
US201261704277P | 2012-09-21 | 2012-09-21 | |
US61/704,277 | 2012-09-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/406,957 A-371-Of-International US11344522B2 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
US17/746,250 Continuation US20220273602A1 (en) | 2012-06-15 | 2022-05-17 | Nutritional product |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013186570A1 true WO2013186570A1 (en) | 2013-12-19 |
Family
ID=46641031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/051561 WO2013186570A1 (en) | 2012-06-15 | 2013-06-14 | Nutritional product |
Country Status (13)
Country | Link |
---|---|
US (2) | US11344522B2 (en) |
EP (3) | EP4371612A3 (en) |
JP (4) | JP2015522256A (en) |
CN (2) | CN107456450A (en) |
AU (6) | AU2013276254A1 (en) |
BR (1) | BR112014031302A2 (en) |
CA (1) | CA2876286C (en) |
DK (1) | DK2861226T3 (en) |
ES (1) | ES2933408T3 (en) |
FI (1) | FI2861226T3 (en) |
GB (1) | GB201210699D0 (en) |
HK (1) | HK1208367A1 (en) |
WO (1) | WO2013186570A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015127320A3 (en) * | 2014-02-20 | 2015-11-12 | Iycus, Llc | Single serve beverage compositions |
WO2016010103A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Baked confectionery that substantially includes no flour |
WO2016010101A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Gel-form emulsified food |
WO2016010102A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Nutritional composition |
CN107427485A (en) * | 2015-02-20 | 2017-12-01 | 雀巢产品技术援助有限公司 | For treating the medium chain fatty acid and its triglycerides of anxiety disorder |
WO2018189113A1 (en) * | 2017-04-10 | 2018-10-18 | Vitaflo International Ltd | Composition for use in the treatment of epilepsy |
WO2019002435A1 (en) * | 2017-06-29 | 2019-01-03 | Vitaflo International Ltd | Combination comprising decanoic acid for the treatment of epilepsy |
EP3313395A4 (en) * | 2015-06-26 | 2019-02-06 | University of Florida Research Foundation, Inc. | Method of treating inflammation using natural compounds and/or diet |
EP3532030A4 (en) * | 2016-10-31 | 2020-04-22 | The Cleveland Clinic Foundation | Capric acid and myristic acid compositions for treating conditions |
US20210145782A1 (en) * | 2015-12-04 | 2021-05-20 | Société des Produits Nestlé S.A. | Medium chain triglyceride compositions |
US11020372B2 (en) | 2015-03-24 | 2021-06-01 | University Of Florida Research Foundation, Incorporated | Dietary and natural product management of negative side effects of cancer treatment |
RU2779202C2 (en) * | 2017-06-29 | 2022-09-05 | Витафло Интернэшнл Лтд | Combination containing decanoic acid for treatment of epilepsy |
EP2861226B1 (en) | 2012-06-15 | 2022-11-02 | Vitaflo International Ltd. | Nutritional product comprising decanoic acid and octanoic acid |
US11666549B2 (en) | 2013-03-14 | 2023-06-06 | University Of Florida Research Foundation, Incorporated | Regulation of cancer using natural compounds and/or diet |
US11738056B2 (en) | 2018-01-23 | 2023-08-29 | The General Hospital Corporation | Compositions and methods for improving mitochondrial function |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018138620A1 (en) * | 2017-01-29 | 2018-08-02 | Gupta Samit | Ketogenic nutritional composition and preparation method thereof |
KR102199688B1 (en) | 2018-11-20 | 2021-01-07 | (주)엠디웰아이엔씨 | Composition for preventing malnutrition or improving nutritional status of patents after surgical procedures |
CN112006273B (en) * | 2020-06-05 | 2023-10-03 | 成都天一美膳营养食品有限公司 | Healthy lipid-reducing meal replacement powder free of ketone production and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
WO2011040342A1 (en) | 2009-09-30 | 2011-04-07 | 日清オイリオグループ株式会社 | Agent for inhibiting decrease of visceral fat in patient with parkinson's disease |
EP2351491A1 (en) | 2008-11-06 | 2011-08-03 | The Nisshin OilliO Group, Ltd. | Concentrated liquid diet |
JP2012097038A (en) * | 2010-11-02 | 2012-05-24 | Kao Corp | Autoinducer-2 inhibitor |
US20160249632A1 (en) | 2013-11-15 | 2016-09-01 | The Nisshin Oillio Group, Ltd. | Improved soy milk and method for producing same |
US20170196229A1 (en) | 2014-07-17 | 2017-07-13 | The Nisshin Oillio Group, Ltd. | Nutritional composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2003425A1 (en) | 1968-03-07 | 1969-11-07 | Unilever Nv | EDIBLE PLASTIC FAT COMPOSITIONS AND PROCESS FOR PREPARING THEM |
CA2361070C (en) | 1999-02-05 | 2012-04-17 | Baylor University Medical Center | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
EP2319508A1 (en) | 2000-05-01 | 2011-05-11 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
JP5447954B2 (en) * | 2007-09-19 | 2014-03-19 | 公益財団法人名古屋産業科学研究所 | Neurotrophic factor-like agent |
EP2249823A4 (en) | 2008-02-15 | 2011-05-18 | Us Gov Health & Human Serv | Octanoic acid formulations and methods of treatment using the same |
GB201020133D0 (en) * | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
GB201210699D0 (en) | 2012-06-15 | 2012-08-01 | Vitaflo Ltd | Nutritional food |
-
2012
- 2012-06-15 GB GBGB1210699.3A patent/GB201210699D0/en not_active Ceased
-
2013
- 2013-06-14 WO PCT/GB2013/051561 patent/WO2013186570A1/en active Application Filing
- 2013-06-14 ES ES13730925T patent/ES2933408T3/en active Active
- 2013-06-14 EP EP24165887.1A patent/EP4371612A3/en active Pending
- 2013-06-14 CA CA2876286A patent/CA2876286C/en active Active
- 2013-06-14 FI FIEP13730925.8T patent/FI2861226T3/en active
- 2013-06-14 DK DK13730925.8T patent/DK2861226T3/en active
- 2013-06-14 US US14/406,957 patent/US11344522B2/en active Active
- 2013-06-14 EP EP22202824.3A patent/EP4162934A1/en active Pending
- 2013-06-14 AU AU2013276254A patent/AU2013276254A1/en not_active Abandoned
- 2013-06-14 JP JP2015516688A patent/JP2015522256A/en active Pending
- 2013-06-14 EP EP13730925.8A patent/EP2861226B1/en active Active
- 2013-06-14 CN CN201710710050.2A patent/CN107456450A/en active Pending
- 2013-06-14 BR BR112014031302A patent/BR112014031302A2/en not_active Application Discontinuation
- 2013-06-14 CN CN201380031426.7A patent/CN104519880A/en active Pending
-
2015
- 2015-09-17 HK HK15109109.2A patent/HK1208367A1/en unknown
-
2018
- 2018-01-18 AU AU2018200433A patent/AU2018200433A1/en not_active Abandoned
- 2018-02-28 JP JP2018035268A patent/JP2018121635A/en active Pending
-
2019
- 2019-09-09 AU AU2019226282A patent/AU2019226282A1/en not_active Abandoned
-
2021
- 2021-03-24 JP JP2021050443A patent/JP2021107394A/en active Pending
- 2021-04-22 AU AU2021202459A patent/AU2021202459B2/en active Active
-
2022
- 2022-05-17 US US17/746,250 patent/US20220273602A1/en active Pending
- 2022-10-17 AU AU2022253500A patent/AU2022253500B2/en active Active
-
2023
- 2023-04-13 JP JP2023065800A patent/JP2023100665A/en active Pending
-
2024
- 2024-07-30 AU AU2024205213A patent/AU2024205213A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
US20070135376A1 (en) | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
EP2351491A1 (en) | 2008-11-06 | 2011-08-03 | The Nisshin OilliO Group, Ltd. | Concentrated liquid diet |
WO2011040342A1 (en) | 2009-09-30 | 2011-04-07 | 日清オイリオグループ株式会社 | Agent for inhibiting decrease of visceral fat in patient with parkinson's disease |
JP2012097038A (en) * | 2010-11-02 | 2012-05-24 | Kao Corp | Autoinducer-2 inhibitor |
US20160249632A1 (en) | 2013-11-15 | 2016-09-01 | The Nisshin Oillio Group, Ltd. | Improved soy milk and method for producing same |
US20170196229A1 (en) | 2014-07-17 | 2017-07-13 | The Nisshin Oillio Group, Ltd. | Nutritional composition |
Non-Patent Citations (13)
Title |
---|
ALONSO L ET AL: "Fatty Acid Composition of Caprine Milk: Major, Branched-Chain, and Trans Fatty Acids", JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION, US, vol. 82, no. 5, 1 May 1999 (1999-05-01), pages 878 - 884, XP026993413, ISSN: 0022-0302, [retrieved on 19990501] * |
ANONYMOUS: "New release of 3 types of "Enepurin" , a food for the elderly that can quickly replenish energy /Nisshin Oillio Group Co., Ltd./Company Profile / News Release", INTERNET ARCHIVE WAYBACK MACHINE, 5 July 2012 (2012-07-05), pages 1 - 2, XP055936449, Retrieved from the Internet <URL:https://web.archive.org/web/20120705203757/http://nisshin-oillio.com/company/news/archive/2012/20120509_141941.shtml> [retrieved on 20220628] |
BAHAR NAZARI: "Fatty acid analysis of Iranian junk food, dairy, and bakery products: Special attention to trans-fats", JOURNAL OF RESEARCH IN MEDICAL SCIENCES, vol. 957, no. 17, 1 October 2012 (2012-10-01), pages 952, XP055075843 * |
BONSER J C, DEAN H G, J P GENT: "THE ANTICONVULSANT ACTIONS OF OCTANOIC AND DECANOIC ACIDS", BRITISH J PHARMACOLOGY, 1 January 1989 (1989-01-01), pages P362, XP055961850 |
BOUGH, K.J., ANN. NEUROL, vol. 60, 2006, pages 223 - 235 |
CHANG P ET AL: "The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium", DISEASE MODELS & MECHANISMS, THE COMPANY OF BIOLOGISTS LTD, GB, vol. 5, no. 1, 18 January 2012 (2012-01-18), pages 115 - 124, XP002667391, ISSN: 1754-8403, [retrieved on 20110829], DOI: 10.1242/DMM.008029 * |
CHANG P, ORABI B, DERANIEH R, DHAM M, HOELLER O, SHIMSHONI J, YAGEN B, BIALER M, GREENBERG M L, WALKER M C, WILLIAMS R S: "The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium.", DISEASE MODELS & MECHANISMS, THE COMPANY OF BIOLOGISTS LTD., GB, vol. 5, no. 1, 18 January 2012 (2012-01-18), GB , pages 115 - 124, XP002667391, ISSN: 1754-8403, DOI: 10.1242/DMM.008029 |
DEAN H G, J C BONSER, J P GENT: "HPLC Analysis of Brain and Plasma for Octanoic and Decanoic Acids", CLIN CHEM ., vol. 35, no. 9, 1 September 1989 (1989-09-01), pages 1945 - 1948, XP055961847 |
HAIDUKEWYCH, DAN; FORSYTHE, W. IAN; SILLS, MICHAEL: "Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet", CLINICAL CHEMISTRY, OXFORD UNIVERSITY PRESS, US, vol. 28, no. 4, 1 April 1982 (1982-04-01), US , pages 642 - 645, XP009171987, ISSN: 0009-9147 |
M A SILLS, W I FORSYTHE, D HAIDUKEWYCH: "Role of octanoic and decanoic acids in the control of seizures.", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 61, no. 12, 1 December 1986 (1986-12-01), pages 1173 - 1177, XP055075892, ISSN: 00039888, DOI: 10.1136/adc.61.12.1173 |
PIOTR WLAZ ET AL: "Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice", NEUROPHARMACOLOGY, vol. 62, no. 4, 1 March 2012 (2012-03-01), pages 1882 - 1889, XP055075889, ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2011.12.015 * |
PISHAN CHANG ET AL: "Seizure control by ketogenic diet-associated medium chain fatty acids", NEUROPHARMACOLOGY, vol. 69, 1 June 2013 (2013-06-01), pages 105 - 114, XP055075887, ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2012.11.004 * |
PISHAN CHANG, NICOLE TERBACH, NICK PLANT, PHILIP E. CHEN, MATTHEW C. WALKER, ROBIN S.B. WILLIAMS: "Seizure control by ketogenic diet-associated medium chain fatty acids", NEUROPHARMACOLOGY, PERGAMON, vol. 69, 1 June 2013 (2013-06-01), pages 105 - 114, XP055075887, ISSN: 00283908, DOI: 10.1016/j.neuropharm.2012.11.004 |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4162934A1 (en) | 2012-06-15 | 2023-04-12 | Vitaflo International Ltd. | Nutritional product |
EP2861226B1 (en) | 2012-06-15 | 2022-11-02 | Vitaflo International Ltd. | Nutritional product comprising decanoic acid and octanoic acid |
US11666549B2 (en) | 2013-03-14 | 2023-06-06 | University Of Florida Research Foundation, Incorporated | Regulation of cancer using natural compounds and/or diet |
WO2015127320A3 (en) * | 2014-02-20 | 2015-11-12 | Iycus, Llc | Single serve beverage compositions |
US20170245514A1 (en) * | 2014-07-17 | 2017-08-31 | The Nisshin Oillio Group, Ltd. | Gel-form emulsified food |
AU2015290595B2 (en) * | 2014-07-17 | 2018-07-05 | The Nisshin Oillio Group, Ltd. | Gel-form emulsified food |
KR20170031151A (en) * | 2014-07-17 | 2017-03-20 | 닛신 오일리오그룹 가부시키가이샤 | Gel-form emulsified food |
CN106535654A (en) * | 2014-07-17 | 2017-03-22 | 日清奥利友集团株式会社 | Baked confectionery that substantially includes no flour |
JP2017070311A (en) * | 2014-07-17 | 2017-04-13 | 日清オイリオグループ株式会社 | Nutritive composition |
JPWO2016010103A1 (en) * | 2014-07-17 | 2017-04-27 | 日清オイリオグループ株式会社 | Baked confectionery substantially free of flour |
JPWO2016010102A1 (en) * | 2014-07-17 | 2017-04-27 | 日清オイリオグループ株式会社 | Nutritional composition |
CN106659220A (en) * | 2014-07-17 | 2017-05-10 | 日清奥利友集团株式会社 | Nutritional composition |
CN106659224A (en) * | 2014-07-17 | 2017-05-10 | 日清奥利友集团株式会社 | Gel-form emulsified food |
US20170196229A1 (en) * | 2014-07-17 | 2017-07-13 | The Nisshin Oillio Group, Ltd. | Nutritional composition |
AU2015290597B2 (en) * | 2014-07-17 | 2017-07-20 | The Nisshin Oillio Group, Ltd. | Baked confectionery that substantially includes no flour |
US20170202239A1 (en) * | 2014-07-17 | 2017-07-20 | The Nisshin Oillio Group, Ltd. | Baked confectionery that substantially includes no flour |
JP2016021889A (en) * | 2014-07-17 | 2016-02-08 | 日清オイリオグループ株式会社 | Gel-like emulsified food |
KR102472964B1 (en) | 2014-07-17 | 2022-12-01 | 닛신 오일리오그룹 가부시키가이샤 | Gel-form emulsified food |
EP3170409A4 (en) * | 2014-07-17 | 2017-12-13 | The Nisshin OilliO Group, Ltd. | Nutritional composition |
JP5976263B2 (en) * | 2014-07-17 | 2016-08-23 | 日清オイリオグループ株式会社 | Baked confectionery substantially free of flour |
WO2016010102A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Nutritional composition |
WO2016010103A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Baked confectionery that substantially includes no flour |
WO2016010101A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Gel-form emulsified food |
CN106535654B (en) * | 2014-07-17 | 2021-04-30 | 日清奥利友集团株式会社 | Baked snack substantially free of flour |
EP3259029B1 (en) | 2015-02-20 | 2020-10-21 | Société des Produits Nestlé S.A. | Medium chain fatty acids and their triglycerides for treating anxiety |
CN107427485B (en) * | 2015-02-20 | 2021-06-18 | 雀巢产品有限公司 | Medium chain fatty acids and triglycerides thereof for the treatment of anxiety disorders |
CN107427485A (en) * | 2015-02-20 | 2017-12-01 | 雀巢产品技术援助有限公司 | For treating the medium chain fatty acid and its triglycerides of anxiety disorder |
US11020372B2 (en) | 2015-03-24 | 2021-06-01 | University Of Florida Research Foundation, Incorporated | Dietary and natural product management of negative side effects of cancer treatment |
EP3313395A4 (en) * | 2015-06-26 | 2019-02-06 | University of Florida Research Foundation, Inc. | Method of treating inflammation using natural compounds and/or diet |
US20210145782A1 (en) * | 2015-12-04 | 2021-05-20 | Société des Produits Nestlé S.A. | Medium chain triglyceride compositions |
US11857527B2 (en) * | 2015-12-04 | 2024-01-02 | Societe Des Produits Nestle S.A. | Medium chain triglyceride compositions |
EP3532030A4 (en) * | 2016-10-31 | 2020-04-22 | The Cleveland Clinic Foundation | Capric acid and myristic acid compositions for treating conditions |
US11826331B2 (en) | 2016-10-31 | 2023-11-28 | The Cleveland Clinic Foundation | Capric acid and myristic acid compositions for treating conditions |
AU2017348410B2 (en) * | 2016-10-31 | 2023-11-02 | The Cleveland Clinic Foundation | Capric acid and myristic acid compositions for treating conditions |
WO2018189113A1 (en) * | 2017-04-10 | 2018-10-18 | Vitaflo International Ltd | Composition for use in the treatment of epilepsy |
RU2793246C2 (en) * | 2017-04-10 | 2023-03-30 | Витафло Интернэшнл Лтд | Composition for use in the treatment of epilepsy |
CN110678173B (en) * | 2017-04-10 | 2023-03-28 | 维塔弗洛国际有限公司 | Composition for treating epilepsy |
US11351138B2 (en) | 2017-04-10 | 2022-06-07 | Vitaflo International Ltd | Composition for use in the treatment of epilepsy |
CN110678173A (en) * | 2017-04-10 | 2020-01-10 | 维塔弗洛国际有限公司 | Composition for treating epilepsy |
AU2018250864B2 (en) * | 2017-04-10 | 2024-01-11 | Ucl Business Ltd | Composition for use in the treatment of epilepsy |
RU2779202C2 (en) * | 2017-06-29 | 2022-09-05 | Витафло Интернэшнл Лтд | Combination containing decanoic acid for treatment of epilepsy |
WO2019002435A1 (en) * | 2017-06-29 | 2019-01-03 | Vitaflo International Ltd | Combination comprising decanoic acid for the treatment of epilepsy |
US11738056B2 (en) | 2018-01-23 | 2023-08-29 | The General Hospital Corporation | Compositions and methods for improving mitochondrial function |
Also Published As
Publication number | Publication date |
---|---|
AU2024205213A1 (en) | 2024-08-15 |
CA2876286C (en) | 2021-03-16 |
US20150164840A1 (en) | 2015-06-18 |
CN104519880A (en) | 2015-04-15 |
AU2018200433A1 (en) | 2018-02-08 |
EP4162934A1 (en) | 2023-04-12 |
EP4371612A3 (en) | 2024-07-31 |
JP2015522256A (en) | 2015-08-06 |
AU2021202459A1 (en) | 2021-05-20 |
DK2861226T3 (en) | 2023-01-30 |
ES2933408T3 (en) | 2023-02-08 |
CN107456450A (en) | 2017-12-12 |
AU2022253500A1 (en) | 2022-11-17 |
HK1208367A1 (en) | 2016-03-04 |
AU2019226282A1 (en) | 2019-09-26 |
US11344522B2 (en) | 2022-05-31 |
CA2876286A1 (en) | 2013-12-19 |
AU2021202459B2 (en) | 2022-07-21 |
JP2023100665A (en) | 2023-07-19 |
EP2861226A1 (en) | 2015-04-22 |
GB201210699D0 (en) | 2012-08-01 |
AU2013276254A1 (en) | 2014-12-18 |
AU2022253500B2 (en) | 2024-05-02 |
BR112014031302A2 (en) | 2017-06-27 |
FI2861226T3 (en) | 2023-01-31 |
JP2021107394A (en) | 2021-07-29 |
EP2861226B1 (en) | 2022-11-02 |
US20220273602A1 (en) | 2022-09-01 |
JP2018121635A (en) | 2018-08-09 |
EP4371612A2 (en) | 2024-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022253500B2 (en) | Nutritional product | |
US9326956B2 (en) | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate | |
EP1800675B1 (en) | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia | |
CN101636167B (en) | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same | |
EP3173089B1 (en) | Agent for improving brain function and agent for preventing cognitive impairment | |
CN107427485B (en) | Medium chain fatty acids and triglycerides thereof for the treatment of anxiety disorders | |
US20130338114A1 (en) | Compositions for increasing strength, muscle mass, and lean body mass | |
CN111616221A (en) | Milk powder for improving memory and relieving pressure and preparation method thereof | |
US20090181974A1 (en) | Composition for slowing down the development of alzheimer's disease | |
EP3972431A1 (en) | Dietary butyrate | |
Kiran et al. | EFFECT OF COW GHEE ON ORAL ABSORPTION OF DRUGS–AN INVITRO COMPARITIVE RESEARCH STUDY | |
EP4262776A1 (en) | Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13730925 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015516688 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2876286 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14406957 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013276254 Country of ref document: AU Date of ref document: 20130614 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014031302 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014031302 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141212 |